Predict your next investment

HEALTHCARE | Biotechnology

See what CB Insights has to offer

Founded Year



Merger | Acquired

Total Raised


About Etiologics

Developer of therapies for chronic respiratory disease. The company's therapeutic interests are in chronic obstructive pulmonary disease (COPD), cystic fibrosis and severe asthma. In November 2002 the company acquired the core respiratory pre-clinical research group from the international pharmaceutical company Bayer. This acquisition also brought a number of assets including some disease models of COPD as well as proprietary automated screening and imaging technologies for following the progression of COPD in these models. The company has built a flexible drug discovery pipeline and aims to apply this knowledge to drive both its own internal drug discovery programme and to partnering this expertise with pharma. A central component to the company's drug discovery pipeline is the development, refinement and exploitation of in vivo models of human disease.

Etiologics Headquarter Location

Stoke Court

Slough, SL2 4LY,

United Kingdom

44 1753 649 400

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.